QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, C.-S. Articles by Waxman, D. J. Search for Related Content PubMed PubMed Citation Articles by Chen, C.-S. Articles by Waxman, D. J.

Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics

Division of Cell and Molecular Biology, Department of Biology, Boston University, Boston, Massachusetts (C.-S.C., J.T.L., K.A.G., D.J.W.); and Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (Y.H., J.R.H.)

Cyclophosphamide (CPA) and ifosfamide (IFA) are oxazaphosphorine anticancer prodrugs metabolized by two alternative cytochrome P450 (P450) pathways, drug activation by 4-hydroxylation and drug inactivation by N-dechloroethylation, which generates the neurotoxic and nephrotoxic byproduct chloroacetaldehyde. CPA and IFA metabolism catalyzed by P450s 2B1, 2B4, 2B5, and seven site-specific 2B1 mutants was studied in a reconstituted Escherichia coli expression system to identify residues that contribute to the unique activities and substrate specificities of these enzymes. The catalytic efficiency of CPA 4-hydroxylation by rat P450 2B1 was 10- to 35-fold higher than that of rabbit P450 2B4 or 2B5. With IFA, 50% of metabolism proceeded via N-dechloroethylation for 2B1 and 2B4, whereas CPA N-dechloroethylation corresponded to only 3% of total metabolism (2B1) or was absent (2B4, 2B5). Improved catalytic efficiency of CPA and IFA 4-hydroxylation was obtained upon substitution of 2B1 Ile-114 by Val, and replacement of Val-363 by Leu or Ile selectively suppressed CPA N-dechloroethylation 90%. P450 2B1-V367A, containing the Ala replacement found in 2B5, exhibited only 10% of wild-type 2B1 activity for both substrates. Canine P450 2B11, which has Val-114, Leu-363, and Val-367, was therefore predicted to be a regioselective CPA 4-hydroxylase with high catalytic efficiency. Indeed, P450 2B11 was 7- to 8-fold more active as a CPA and IFA 4-hydroxylase than 2B1, exhibited a highly desirable low K_m (80-160 µM), and catalyzed no CPA N-dechloroethylation. These findings provide insight into the role of specific P450 2B residues in oxazaphosphorine metabolism and pave the way for gene therapeutic applications using P450 enzymes with improved catalytic activity toward these anticancer prodrug substrates.

Received November 19, 2003; accepted February 9, 2004.

Address correspondence to: Dr. David J. Waxman, Department of Biology, Boston University, Boston, MA 02215. E-mail: djw{at}bu.edu

This article has been cited by other articles:

				T.-A. Nguyen, M. Tychopoulos, F. Bichat, C. Zimmermann, J.-P. Flinois, M. Diry, E. Ahlberg, M. Delaforge, L. Corcos, P. Beaune, et al. Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex Vivo Mol. Pharmacol., April 1, 2008; 73(4): 1122 - 1133. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib Mol. Cancer Ther., January 1, 2008; 7(1): 79 - 89. [Abstract] [Full Text] [PDF]

				J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]

				J. Gu, C.-S. Chen, Y. Wei, C. Fang, F. Xie, K. Kannan, W. Yang, D. J. Waxman, and X. Ding A Mouse Model with Liver-Specific Deletion and Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: Characterization and Utility for in Vivo Studies of Cyclophosphamide Disposition J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 9 - 17. [Abstract] [Full Text] [PDF]

				Y. Jounaidi, C.-S. Chen, G. J. Veal, and D. J. Waxman Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol. Cancer Ther., March 1, 2006; 5(3): 541 - 555. [Abstract] [Full Text] [PDF]

				C.-S. Chen, Y. Jounaidi, and D. J. Waxman ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OF R-IFOSFAMIDE AND S-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450 Drug Metab. Dispos., September 1, 2005; 33(9): 1261 - 1267. [Abstract] [Full Text] [PDF]

				S. Kumar, C. S. Chen, D. J. Waxman, and J. R. Halpert Directed Evolution of Mammalian Cytochrome P450 2B1: MUTATIONS OUTSIDE OF THE ACTIVE SITE ENHANCE THE METABOLISM OF SEVERAL SUBSTRATES, INCLUDING THE ANTICANCER PRODRUGS CYCLOPHOSPHAMIDE AND IFOSFAMIDE J. Biol. Chem., May 20, 2005; 280(20): 19569 - 19575. [Abstract] [Full Text] [PDF]